Information de reference pour ce titreAccession Number: | 01445386-200501150-00013.
|
Author: | Nakanishi, Kazuaki M.D., Ph.D. 1,2; Sakamoto, Michiie M.D., Ph.D. 1,3; Yamasaki, Susumu M.D., Ph.D. 4; Todo, Satoru M.D., Ph.D. 2; Hirohashi, Setsuo M.D., Ph.D. *,1,+
|
Institution: | (1)Division of Pathology, National Cancer Center Research Institute, Tokyo, Japan (2)Department of General Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan (3)Department of Pathology, Keio University School of Medicine, Tokyo, Japan (4)Division of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan
|
Title: | |
Source: | Cancer. 103(2):307-312, January 15, 2005.
|
Author Keywords: | hepatocellular carcinoma; early disease recurrence; poor prognosis; immunostaining; phosphorylated Akt.
|
References: | 1. Nagao T, Inoue S, Goto S, et al. Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. Ann Surg. 1987; 205: 33-40.
2. Nagao T, Inoue S, Yoshimi F, et al. Postoperative recurrence of hepatocellular carcinoma. Ann Surg. 1990; 211: 28-33.
3. Sakon M, Umeshita K, Nagano H, et al. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg. 2000; 135: 1456-1459.
4. Ikeda Y, Kajiyama K, Adachi E, Yamagata M, Shimada M, Yanaga K. Early recurrence after surgery of hepatocellular carcinoma. Hepatogastroenterology. 1995; 42: 469-472.
5. Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology. 1989; 9: 457-460.
6. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000; 89: 500-507.
7. Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology. 1991; 14: 802-805.
8. Yamanaka J, Yamanaka N, Nakasho K, et al. Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection. J Gastroenterol Hepatol. 2000; 15: 1192-1198.
9. Nakanishi K, Sakamoto M, Yasuda J, et al. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res. 2002; 62: 2971-2975.
10. Kanai T, Hirohashi S, Upton MP, et al. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer. 1987; 60: 810-819.
11. Mangham DC, Isaacson PG. A novel immunohistochemical detection system using mirror image complementary antibodies (MICA). Histopathology. 1999; 35: 129-133.
12. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991; 254: 274-277.
13. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res. 1999; 253: 210-229.
14. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999; 13: 2905-2927.
15. Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK. The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci USA. 1998; 95: 14950-14955.
16. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA. 1987; 84: 5034-5037.
17. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995; 64: 280-285.
18. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA. 1996; 93: 3636-3641.
19. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog. 1998; 21: 81-86.
20. Yamanaka N, Okamoto E, Fujihara S, et al. Do the tumor cells of hepatocellular carcinomas dislodge into the portal venous stream during hepatic resection? Cancer. 1992; 70: 2263-2267.
21. Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer. 1990; 65: 1104-1110.
22. Hanazaki K, Wakabayashi M, Sodeyama H, Kajikawa S, Amano J. Hepatic function immediately after hepatectomy as a significant risk factor for early recurrence in hepatocellular carcinoma. Hepatogastroenterology. 1999; 46: 3201-3207.
23. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999; 229: 216-222.
24. Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology. 1996; 111: 720-726.
25. Takata M, Yamanaka N, Tanaka T, et al. What patients can survive disease free after complete resection for hepatocellular carcinoma? A multivariate analysis. Jpn J Clin Oncol. 2000; 30: 75-81.
26. Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K, Sugimachi K. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology. 1995; 22: 1702-1707.
27. Oda T, Tsuda H, Sakamoto M, Hirohashi S. Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence [sic] for multistage progression. Cancer Lett. 1994; 83: 197-200.
|
Language: | English.
|
Document Type: | Original Articles.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0008-543X
|
DOI Number: | https://dx.doi.org/10.1002/cncr....- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|